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Abbreviation list 
AKI: acute kidney injury 
ART: Arterial Revascularization Trial  
BMI: body mass index  
BITA: bilateral internal thoracic artery  
CK-MB: creatine kinase MB  
CVA: cerebrovascular accident  
COPD: chronic obstructive pulmonary disease  
LMD: left main disease  
LVEF: left ventricular ejection fraction 
MACCE: major cardiac and cerebrovascular events  
MI: myocardial infarction  
ONCAB: on-pump coronary artery bypass 
OPCAB: off-pump coronary artery bypass  
SITA: single internal thoracic artery  
PCI: percutaneous coronary intervention 
PSM: Propensity score matching 
RBC: red blood cell 
PVD: peripheral vascular disease  
SMD: standardized mean difference 
SVG: saphenous vein graft  
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Central message: Off-pump and on-pump coronary artery bypass grafting are comparable in 
terms of 5-year rate of death and major cardiac and cerebrovascular events.   
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Perspective statement: Some studies have reported increased adverse event rates with off-
pump when compared to on-pump coronary artery bypass. The present post-hoc analysis of the 
ART trial found no significant difference between off-pump and on-pump coronary surgery in 
the rate of death and major cardiac and cerebrovascular events.    
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Abstract 
Background: The long-term effects of (OPCAB) continue to be controversial as some studies 
have reported increased adverse event rates with OPCAB when compared to on-pump coronary 
artery bypass (ONCAB). The Arterial Revascularization Trial (ART) compared survival after 
bilateral versus single internal thoracic artery grafting. The choice of OPCAB versus ONCAB 
was based on surgeon’s discretion. We performed a post-hoc analysis of the ART to compare 
5-year outcomes with two strategies.  
Methods: Among 3102 patients enrolled in the ART, we selected 1260 patients who underwent 
OPCAB versus 1700 patients who underwent ONCAB with cardioplegic arrest for the preent 
comparison. Primary outcomes were 5-year mortality and incidence of major cardiac and 
cerebrovascular events (MACCE) including cardiovascular death, myocardial infarction, 
cerebrovascular accident and revascularization after index procedure. Propensity score 
matching selected 1260 pairs for final comparison. Stratified Cox models were used for 
treatment effect estimate.  
Results: Hospital mortality was comparable between OPCAB and ONCAB groups (12[1.0%] 
vs 15[1.2%]; P=0.7). Conversion rate to on pump during OPCAB was 29/1260 (2.3%). When 
compared to OPCAB not converted, OPCAB converted to on-pump presented a remarkably 
higher hospital mortality (10.3% vs 0.7%; P<0.001). At 5 years, mortality rate was 110(8.9%) 
vs. 102(8.3%) in the OPCAB and ONCAB groups respectively with no significant difference 
(hazard ratio, HR 1.14; 95% confidence interval, CI 0.86-1.52; P=0.35). Incidence of MACCE 
was 175(14.3) vs. 169 (13.8) in the in the OPCAB and ONCAB groups respectively with no 
significant difference (HR 1.05; 95%CI 0.84-1.31; P=0.65). 
Conclusions: The present post-hoc ART analysis supports the hypothesis that both OPCAB 
and ONCAB are equally effective and safe.  
 6 
 
Despite the potential advantages of avoiding cardiopulmonary bypass, the postulated benefits 
of off-pump coronary artery bypass (OPCAB) in terms of perioperative mortality and 
morbidity including stroke were not realized in the majority of studies comparing the two 
strategies [1]. Furthermore, the long-term effects of OPCAB continue to be controversial. The 
increased technical complexity of OPCAB can result in less complete revascularization and 
reduced graft patency rates with some studies reporting increased adverse event rates with 
OPCAB when compared to on-pump coronary artery bypass (ONCAB) [2-5]. 
Two large randomized controlled trials (RCT) comparing OPCAB vs ONCABG have recently 
reported conflicting findings. The CABG Off or On Pump Revascularization Study 
(CORONARY) [6] has recently shown comparable 5 years results between the two techniques. 
However, CORONARY enrolled only higher risk patients and this aspect may limit the 
generalizability of the study findings. On the other hand, the Department of Veterans Affairs 
"Randomized On/Off Bypass" (ROOBY) Trial [7] has reported increased 5 years mortality 
with OPCAB. However, the ROOBY trial was criticized for the fact that the conversion rate to 
cardiopulmonary bypass was unacceptably high at 12 % and this brought some skepticism on 
the level of “off pump” experience of the surgeons involved in the study. 
Consequently, the question whether OPCAB increases the risk of adverse events over the 
longer term when compared to ONCAB continues. The Arterial Revascularization Trial (ART) 
is designed to compare 10-year survival after bilateral internal thoracic artery (BITA) versus 
single left internal thoracic artery (SITA) grafting and an interim report at 5 years has not 
shown any clear difference between the two groups [8]. In the ART, the choice of OPCAB 
versus ONCAB was based on surgeon’s discretion. We sought to get further insights into the 
comparison between the two strategies by performing a post-hoc analysis of the ART.  
Materials and Methods 
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The present study is a post-hoc retrospective analysis of 5 year outcomes of the ART trial. This 
research adheres to the principles set forth in the Declaration of Helsinki 
(http://www.wma.net/en/30publications/10policies/b3/index.html). In the ART, the choice of 
OPCAB versus ONCAB was based on surgeon’s discretion. OPCAB versus ONCAB strategy 
adopted was available for all patients enrolled. Among patients enrolled in the ART (n=3102) 
from 2004 to 2007, we excluded those who did not undergo surgery (n=23). In two cases, there 
was no information regarding the use of cardiopulmonary bypass. We also excluded patients 
who received on-pump beating heart surgery (n=19) and 95 patients who received cross clamp 
fibrillation.  The present analysis compared 1260 patients who underwent OPCAB versus 1700 
patients who underwent ONCAB with cardioplegic arrest. OPCAB cases requiring 
intraoperative conversion to on-pump were included in the OPCAB group in the primary 
analysis (Figure 1). A total of 156 surgeons were involved. For 134 patients (60 OPCAB, 74 
ONCAB) no information on participating surgeon was available. The total number of 
procedures performed by each surgeon and the choice between OPCAB vs. ONCAB presented 
a large variation with a large proportion of surgeons performing only few procedures 
(Supplementary Table 1). No information was available on individual surgeon practice pattern 
and OPCAB experience before they took part to the trial (i.e. number of OPCAB vs ONCAB 
procedure performed per year).  
Trial design 
The ART has been approved by the institutional review board of all participating centres, and 
informed consent was obtained from each participant. The protocol for the ART has been 
published [9]. Briefly, the ART is a 2-arm, randomized multi centre trial conducted in 28 
hospitals in 7 countries, with patients being randomized equally to SITA or bilateral internal 
thoracic artery (BITA) grafts. Eligible patients were those with multivessel coronary artery 
disease undergoing coronary artery bypass grafting including urgent patients. Only emergency 
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patients (refractory myocardial ischemia/cardiogenic shock) and those requiring single grafts 
or redo surgery were excluded.  
Follow-up  
Questionnaires were sent to study participants by post at 12 months and then every year after 
surgery. No clinic visits were planned apart from the routine clinical 6-week post-operative 
visit. Participants were sent stamped addressed envelopes to improve the return rates of postal 
questionnaires. Study coordinators contacted participants by telephone to alert them to the 
questionnaire’s arrival and to ask them about medications, adverse events and health services 
resource use. Mean follow-up time for the present analysis was 4.9±1.0 years. Follow-up at 5 
years was completed for 2833/2960 (96%) patients.   
Study outcomes  
The two strategies were compared in terms of hospital outcomes and 5 years mortality and 
incidence of major cardiac and cerebrovascular events (MACCE) which included 
cardiovascular death, non-fatal myocardial infarction (MI), non-fatal cerebrovascular accident 
(CVA) and repeat revascularization. Treatment effect on individual MACCE components was 
also investigated. Adverse events were adjudicated blind to surgical procedure by a member of 
the Clinical Event Review Committee.  
Outcomes definitions 
Death was classified into cardiovascular and non-cardiovascular, where possible, using 
autopsy reports and death certificates. Congestive heart failure, arrhythmia or myocardial 
infarction, pulmonary embolus and dissection were considered cardiovascular causes of death.  
MI was diagnosed when two of the following three criteria were present: 1. Unequivocal ECG 
changes; 2. Elevation of cardiac enzyme(s) above twice the upper limit of normal or diagnostic 
troponin rises; 3. Chest pain typical for acute MI which lasted more than 20 minutes.  CVA 
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was defined as new neurological deficit evidenced by clinical signs of paresis, plegia or new 
cognitive dysfunction including any mental status alteration lasting more than 24 hours and/or 
evidence on CT or MRI scan of recent brain infarct (less than 6 months). Repeat 
revascularization was defined as coronary bypass surgery or percutaneous coronary 
intervention (PCI) performed after trial procedure. Acute kidney injury (AKI) defined as a 0.3 
mg/dl (≥26.5 mmol/l) creatinine increase from baseline within 48 hours of surgery.  
Statistical analysis  
Multiple imputation (m=3) was used to address missing data. Rubin’s method [10] was used 
to combine results from each of the imputed data sets (Amelia R package). Due to lack of 
randomization with regards to receiving OPCAB, a propensity score (PS) was generated for 
each patient from a multivariable logistic regression model based on 23 pre-treatment 
covariates as independent variables with OPCAB versus ONCAB as a binary dependent 
variable [10]. Pairs of patients were derived using greedy 1:1 matching with a calliper of width 
of 0.2 standard deviation of the logit of the PS (nonrandom R package). The quality of the 
match was assessed by comparing selected pre-treatment variables in propensity score–
matched patients using the standardized mean difference (SMD), with an absolute standardized 
difference of greater than 10% taken to represent meaningful covariate imbalance. [11]. 
McNemar's test and paired t-test was used to assess the statistical significance of the risk 
difference for hospital outcomes [12]. Cox regression models stratified on the matched pairs 
[12] were used to estimate the treatment effect on 5 years outcomes respectively. This approach 
accounts for the within-pair homogeneity by allowing the baseline hazard function to vary 
across matched sets. Risk competing framework was used to estimate the treatment effect on 
MACCE individual components. The Schoenfeld residuals test was used to test the 
independence between residuals and time and hence to test the proportional hazards assumption 
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in Cox models (survival R package). All p-values <0.05 were considered to indicate statistical 
significance.  
Due to the large number of participating surgeons and the marked variability of total number 
of procedures and OPCAB procedures performed individually, performing surgeons could not 
be included into PS model. To account for the potential influence of individual surgeon’s 
OPCAB experience, we classified each patient according to quartiles of total number of 
OPCAB procedures performed in the trial by the relative surgeon (0 [on-pump only], 1-5 [small 
OPCAB volume], 6-60 [moderate OPCAB volume], >60 [high OPCAB volume]) and 
outcomes in the matched sample were reported accordingly for descriptive purpose. Finally 
baseline characteristics and outcomes between OPCAB cases converted to on pump vs. not 
converted were also reported. All statistical analysis was performed using R Statistical 
Software (version 3.2.3; R Foundation for Statistical Computing, Vienna, Austria). 
Results 
Patient’s characteristics and operative data.  
OPCAB group was more likely to have higher creatinine and to receive BITA graft and was 
less likely to have treated hypertension, history of smoking and to receive saphenous vein graft. 
Total number of grafts per patients was comparable in the OPCAB and ONCAB groups 
(3.20±0.97 vs. 3.19±0.76; P=0.7). However, in the OPCAB group, the right coronary artery 
was less likely to be revascularized (62.1% vs 73.4%; P<0.001) whilst diagonal branches were 
more likely to be grafted in the OPCAB group (35.7% vs 29.2%; P<0.001). The two groups 
did not differ for rate of left anterior descending artery (98.1% vs 98.7%; P=0.24) and 
circumflex artery grafting (91.8% vs 92.6%; P=0.45).  
PSM selected 1260 matched pairs for final comparison (C statistic=0.71; Supplementary 
Figure 1). No residual imbalance was observed between matched groups (all SMD<10%) 
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(Table 1 and Supplementary Figure 2). After matching number of grafts in the OPCAB and 
ONCAB groups was comparable (3.20±0.97 vs. 3.17±0.87; P=0.35) 
Hospital outcomes 
Hospital outcomes comparisons before and after matching are reported in Table 2. In hospital 
mortality was low and comparable between OPCAB and ONCAB groups (1.0% vs 1.2% 
P=0.70). OPCAB was associated with a lower creatine kinase MB (CK-MB) peak at 24hrs 
postoperatively and a relative lower incidence of MI. However, the rate of intra-aortic balloon 
pump requirement was comparable between the two groups. OPCAB was associated with a 
lower rate of red blood cell (RCB) transfusion and a trend towards a lower incidence of sternal 
wound complication. OPCAB did not reduce the incidence of postoperative CVA, AKI and 
renal replacement therapy.  
5-year outcomes  
5-year outcomes comparisons before and after matching are reported in Table 3. 5-year 
mortality (hazard ratio, HR 1.14; 95% confidence interval, CI 0.86-1.52; P=0.35; Figure 2) and 
MACCE risk (HR 1.05; 95%CI 0.84-1.31; P=0.65) was comparable between the two groups. 
In terms of individual MACCE components, OPCAB was associated with a marginally non-
significant 1.1% absolute risk reduction in MI. CV death, CVA and repeat revascularization 
rates were comparable between the two groups (Figure 3).  
Impact of intraoperative conversion to on-pump on outcomes   
Intraoperative conversion to on-pump occurred for 29 out of 1260 OPCAB (2.3%) procedures. 
Notably, distribution of risk factors between the OPCAB converted to on-pump group and 
OPCABG not converted group was similar (Supplementary Table 2). When compared to 
OPCAB not converted, OPCAB converted to on-pump presented a remarkably higher hospital 
mortality (10.3% vs 0.7%; P<0.001) and increased rate of hospital complications despite 
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similar distribution of baseline risk factors. The trend towards poorer outcomes among OPCAB 
cases converted to on-pump persisted at 5 years (Supplementary Table 3, Supplementary 
Figure 3).  
Surgeon OPCAB volume and outcomes  
A total of 95 surgeons performed on-pump only (951 patients); 33 surgeons performed between 
1 and 5 OPCAB procedures (531 patients; 62 OPCAB; 469 ONCAB); 25 surgeons performed 
between 6 and 60 OPCAB procedures (in total 779 patients; 530 OPCAB; 249 ONCAB); 
finally, 3 surgeons performed over 60 OPCAB procedures (in total 699 patients; 668 OPCAB; 
31 ONCAB)  
Baseline characteristics and outcomes in the matched OPCAB and ONCAB groups stratified 
per surgeon OPCAB volume are reported in Supplementary Table 4 and Supplementary Table 
5 and Supplementary Figure 4. OPCAB cases performed by “sporadic” OPCAB surgeons (1-
5 OPCAB procedures) presented a high rate of conversion (12.9%), a lower number of grafts 
performed (2.60±0.88) and a higher rate of operative mortality (4.8%) compared to other 
OPCAB subgroups despite risk factors distribution was similar.    
When OPCAB performed by 3 high volume OPCAB surgeons (>60) was compared to ONCAB 
by 95 “on-pump only” surgeons performing on-pump only we found similar 5-year overall 
mortality and MACCE rates.    
Among 28 ONCAB cases performed by 3 high OPCAB volume surgeons (>60), we observed 
a high hospital mortality rate (7.1%). However, this subgroup presented a higher prevalence of 
important risk factors including LVEF <30% and increased creatinine compared to other 
ONCAB subgroups suggesting that these 3 surgeons selectively used on-pump for high risk 
cases. 
Discussion  
 13 
 
The main finding of the present post-hoc analysis of the ART showed that when compared to 
ONCAB, OPCAB was associated with comparable number of grafts performed, a reduced 
operative morbidity and comparable 5-year mortality and incidence of MACCE. Conversion 
rate to on-pump was relatively low (2.3%) but was associated with a remarkable increase in 
hospital mortality and morbidity and poorer 5-year outcomes.  
In the ART, over 50% of OPCAB procedures (668/1260) were performed by 3 surgeons only 
among 156 participating surgeons while 95 surgeons performed on-pump only. OPCAB 
performed by 3 high volume OPCAB surgeons was associated to hospital and 5-year mortality 
comparable to those observed after ONCAB performed by 95 “on-pump only” surgeons.  
We found that OPCAB performed by “sporadic” OPCAB surgeons (between 1 and 5 OPCAB 
procedure) was associated with a marked increase in conversion rate (12.9%), a lower number 
of graft performed and increased hospital mortality (4.8%).    
There is continued debate as to whether OPCAB may affect long-term outcomes due to a lower 
number of graft performed and subsequent effect of incomplete revascularization. Takagi et al. 
[2] pooled 5 randomized controlled trials and 17 adjusted observational studies that had 
reported long-term (≥5-year) all-cause mortality. In observational studies (102,820 patients) 
but not in randomized trials (1486 patients), OPCAB was associated with increased late 
mortality. 
Criticisms for observational studies comparing OPCAB and ONCAB include a possible bias 
toward including higher-risk patients in the OPCAB group [13]. Furthermore, incomplete 
revascularization in retrospective studies may be a surrogate marker for higher burden of 
comorbidities and per se might not be particularly relevant on patients’ outcome [14].  
The CORONARY trial [6] is a large trial (n=4502 patients) designed to compare the two 
strategies.  The final 5-year results showed similar outcomes with OPCAB and ONCAB. The 
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difference between OPCAB and ONCAB in terms of number of grafts (3.0 vs. 3.2) and 
incidence of incomplete revascularization (11.8% vs. 10.0%) was only marginal. In the 
CORONARY, each procedure was performed by a surgeon who had expertise in the specific 
type of surgery (completion of more than 100 cases of the specific technique either off-pump 
or on-pump). A limitation of the CORONARY is that only patients at higher risk were enrolled 
and this aspect might limit the generalizability of the study findings.    
In contrast, in the ROOBY trial [7], which enrolled 2203 patients, OPCAB has been recently 
reported to be associated with increased 5-year mortality (15.2% in the OPCAB group versus 
11.9% in the ONCAB group, relative risk, 1.28; 95% CI, 1.03 to 1.58; P=0.02). and MACCE 
rates (31.0% in the OPCAB group versus 27.1% in the ONCAB group (relative risk, 1.14; 95% 
CI, 1.00 to 1.30; P=0.046). This trial has also demonstrated that the patency rate of the off-
pump arm was lower than that of the on-pump arm on 12-month angiography [15]. Such 
findings can be partially explained on the basis that the 53 participating surgeons enrolled on 
average only eight patients per year during the study period and had unacceptably high 
conversion rates to on-pump surgery (12%) and incomplete revascularization (18%). 
Moreover, in 60% of the cases, a resident was the primary surgeon again raising concerns about 
the relative inexperience translating into poor graft patency. 
The present post-hoc analysis supports the equipoise between OPCAB and ONCAB in term of 
safety and efficacy. We found a trend towards a lower incidence of MI in the OPCAB group 
mainly related to early phase. It is well recognized that OPCAB is associated with a lower 
release of myocardial enzymes [16] but the clinical relevance of this observation remains 
unclear. Moreover, the definition of perioperative MI following myocardial revascularization 
remains controversial as well as its clinical implication [17].    
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In the ART, over 50% of OPCAB procedures were performed by 3 high volume OPCAB 
surgeons only and this can partially explain the present findings. When OPCAB was performed 
by “sporadic” off-pump surgeons, this was associated with a lower number of grafts, higher 
conversion rate and higher hospital mortality. This observation supports the central role of 
surgeon expertise in determining short and long-term results after off-pump.    
The unique technical challenges of OPCAB fuel the perception that adoption of this myocardial 
revascularization strategy may lead to poorer outcomes during each surgeon’s “learning curve” 
[18]. However, learning curve in off-pump CABG can be safely negotiated with appropriate 
patient selection, individualized grafting strategy, peer-to-peer training of the entire team, and 
graded clinical experience. Centers with established off-pump training programs have 
consistently shown that OPCAB can be safely and successfully taught to trainees without 
jeopardizing outcomes [19]. 
In the current era, increasing number of patients with high-risk profile is being referred for 
surgical myocardial revascularization and off-pump represents an attractive strategy to reduce 
operative morbidity especially in this subgroup as recently supported by a large meta-analysis 
of RCTs [20]. Therefore, OPCAB should remain in the armamentarium of cardiac surgeons 
(video 1). However, these superior outcomes in high-risk patients can only be achieved if off-
pump is offered to high- and low-risk patients alike and this further emphasizes the need for 
recognition of off-pump as a subspecialty with structured training program.  
The present analysis has intrinsic limitations. The main limitation is the retrospective analysis. 
The propensity technique can adjust only for measurable and included variables, and we cannot 
exclude a selection bias based on a nonmeasurable ‘‘eye-balling’’ including the quality of the 
targets. We had no information on specific surgeon off-pump expertise and we used total 
number of off-pump procedures performed in the ART as surrogate of off-pump expertise. 
 16 
 
However, the validity of this approach was further limited by the large variability of number 
of procedures performed per surgeon with a large proportion of surgeons performing less than 
5 procedures (67 over 156 surgeons). Moreover, we had no information on reasons for 
preferring off-pump over on-pump and vice-versa across surgeon subgroups. Therefore, 
subgroup analysis based on surgeon OPCAB volume should be considered only as descriptive 
and hypothesis generating. Despite the present analysis did not show a significant difference 
in terms of mortality between the two strategies, there is a marginal trend towards an excess of 
cardiovascular deaths in the OPCAB group (4.1% vs. 3.1%) and it can be argued that the 
present analysis is underpowered to demonstrate a significant difference between the two 
groups. However, this difference is irrelevant when all-cause mortality is considered (8.9% vs 
8.3%). All-cause death is the most robust and unbiased index in cardiovascular research 
because no adjudication is required, thus avoiding inaccurate or biased documentation and 
inconsistency in endpoint definition.  
In conclusion, the present post-hoc ART analysis, found no significant difference at 5 years 
between the OPCAB and ONCAB in the rate of death, nonfatal stroke, nonfatal myocardial 
infarction or in the rate of subsequent revascularization procedures. Our results indicate that 
both procedures are equally effective and safe at least over the medium term. 
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Table 1. Baseline characteristics of patients undergoing OPCAB vs ONCAB  
OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary artery bypass; SMD: 
standardized mean difference; PSM: propensity score matching; SBP: systolic blood pressure; 
DPB: diastolic blood pressure; COPD: chronic obstructive pulmonary disease; PVD: 
peripheral vascular disease; TIA: transient ischemic attack; CVA: cerebrovascular accident; 
MI: myocardial infarction; PCI: percutaneous coronary intervention; AF: atrial fibrillation; 
LVEF: left ventricular ejection fraction; LMD: left main disease; RA: radial artery BITA: 
Bilateral internal thoracic arteries, SVG: saphenous vein graft 
  
 OPCAB ONCAB 
unmatched 
SMD 
Pre-
PSM 
ONCAB 
matched 
SMD 
Post 
PSM 
n  1260 1700  1260  
Age (years) mean (sd)  64 (9) 64 (9) 1 64 (9) 1 
Female n(%) 180 (14.3) 240 (14.1) 0 180 (14.3) 0 
BMI mean (sd)  28.10 (4.10) 28.28 (3.87) 5 28.13 (3.87) 1 
SBP (mmHg) mean (sd)  133 (19) 131 (17) 9 132.30 (18) 2 
DBP (mmHg) mean (sd)  75 (11) 75 (11) 5 75.24 
(11.32) 
-1 
Creatinine (mmol/l) mean (sd)  100 (23) 94 (21) 26 97.75 
(21.58) 
9 
Treated Hypertension n(%) 943 (75) 1360 (80.0) -12 950 (75.4) -1 
Treated Hyperlipaemia n(%) 1176 (93.3) 1601 (94.2) -4 1178 (93.5) -1 
Diabetes n(%)    -6  1 
   No 980 (77.8) 1286 (75.6)  983 (78.0)  
   Insulin dependent  70 ( 5.6) 93 ( 5.5)  67 ( 5.3)  
   Non-insulin dependent   210 (16.7) 321 (18.9)  210 (16.7)  
Smoking n(%)    -14  -9 
   Current 180 (14.3) 242 (14.2)  149 (11.8)  
   Ex-smoker  664 (52.7) 999 (58.8)  723 (57.4)  
   Never   416 (33.0) 459 (27.0)  388 (30.8)  
COPD n(%) 29 ( 2.3) 43 ( 2.5) -2 28 ( 2.2) 1 
Asthma n(%) 63 ( 5.0) 65 ( 3.8) 6 59 ( 4.7) 2 
PVD n(%) 90 ( 7.1) 120 ( 7.1) 0 81 ( 6.4) 3 
TIA n(%) 40 ( 3.2) 60 ( 3.5) -2 40 ( 3.2) 0 
CVA n(%) 40 ( 3.2) 46 ( 2.7) 3 38 ( 3.0) 1 
MI n(%) 510 (40.5) 726 (42.7) - 5 513 (40.7) -1 
PCI n(%) 208 (16.5) 270 (15.9) 2 214 (17.0) -1 
Preop AF n(%) 19 ( 1.5) 24 ( 1.4) 1 16 ( 1.3) 2 
preop LVEF (%)    5  2 
     ≥50% (good)  950 (75.4) 1289 (75.8)  939 (74.5)  
     31-49% (moderate)  268 (21.3) 389 (22.9)  303 (24.0)  
     ≤30% (poor)  42 ( 3.3) 22 ( 1.3)  18 ( 1.4)  
LMD n(%) 282 (22.4) 356 (20.9) 4 277 (22.0) 1 
RA n(%) 240 (19.0) 381 (22.4) -8 252 (20.0) -2 
SVG n(%) 936 (74.3) 1344 (79.1) -11 956 (75.9) -4 
BITA n(%) 598 (47.5) 691 (40.6) 14 575 (45.6) 4 
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Table 2. Hospital outcomes of patients undergoing OPCAB vs ONCAB in the ART 
 
 
OPCAB ONCAB 
unmatched 
P-value* 
Pre-PSM  
ONCAB 
matched 
P-valueǂ 
Post-
PSM 
n  1260 1700  1260  
Death n(%)  12 (1.0) 18 (1.1) 0.92 15 (1.2) 0.70 
CVA n(%)  20 (1.6) 19 (1.1) 0.34 13 (1.0) 0.29 
Periop MI n(%)  10 (0.8) 40 (2.4) 0.002 32 (2.5) 0.001 
CK-MB 24h (U/L) mean (sd)  34 (179) 80 (125) 0.007 83 (139) 0.02 
IABP insertion n(%)  58 (4.6) 59 (3.5) 0.14 46 (3.7) 0.27 
Repeat Revascularization n(%)  8 (0.6) 7 (0.4) 0.56 7 (0.6) 1 
POAF n(%)  279 (22.1) 451 (26.5) 0.007 333 (26.4) 0.01 
Renal replacement therapy n(%)  72 (5.7) 79 (4.6) 0.22 64 (5.1) 0.54 
AKI n(%)  225 (17.9) 290 (17.1) 0.61 221 (17.5) 0.88 
Sternal wound complication n(%)  35 (2.8) 67 (3.9) 0.11 52 (4.1) 0.08 
Reexploration for bleeding n(%)  40 (3.2) 62 (3.6) 0.55 51 (4.0) 0.29 
RBC transfusion n(%) 165 (13.1) 280 (16.5) 0.01 207 (16.4) 0.02 
OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary artery bypass; PSM: 
propensity score matching; MI: myocardial infarction; CK-MB creatine kinase-MB; IABP: 
intra-aortic balloon pump; POAF: postoperative atrial fibrillation; AKI: acute kidney injury; 
RBC: red blood cell 
*Chi test or t-test 
ǂ  Mcnemar test or paired t-test 
 
  
 22 
 
Table 3. 5-year outcomes of patients undergoing OPCAB vs ONCAB in the ART (expressed 
in number of events and cumulative incidence) 
 OPCAB ONCAB 
unmatched 
ONCAB  
Matched 
HR(95%CI) 
Post-PSM* 
P-value 
Post-
PSM* 
n  1260 1700 1260   
Mortality n(%) 110(8.9) 134(8.0) 102(8.3) 1.14[0.86-1.52] 0.35 
MACCE n(%) 175(14.3) 217(13.1) 169 (13.8) 1.05 [0.84-1.31] 0.65 
CV death n(%) 51(4.1) 47(2.8) 39(3.1) 1.39[0.90-2.13] 0.13 
MI n(%) 37(3.0) 61(3.6) 51(4.1) 0.66[0.43-1.02] 0.06 
CVA n(%) 41(3.3) 42(2.5) 32(2.6) 1.32[0.83-2.11] 0.24 
Revascularization n(%)  90(7.5) 108(6.4) 84(6.8) 1.09[0.80-1.49] 0.58 
OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary artery bypass; PSM: 
propensity score matching; MACCE: major cardiac and cerebrovascular event; CV: 
cardiovascular; MI: myocardial infarction; CVA: cerebrovascular accident 
*Cox model stratified for matched pairs  
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Table 4. Outcomes in patients undergoing OPCAB converted vs non-converted to on-pump 
 OPCAB 
converted to  
on-pump 
OPCAB not 
converted  
 
P-value 
N 29 1231  
In hospital outcomes*    
   Death n(%)  3 (10.3) 9 ( 0.7) <0.001 
   CVA n(%) 1 ( 3.4) 19 ( 1.5) 0.95 
   MI n(%) 0 ( 0.0) 10 ( 0.8) 1 
   CKMB at 24h (U/L) mean (sd)  182 (102) 31 (179) 0.15 
   IABP insertion n(%) 10 (34.5) 48 ( 3.9) <0.001 
  Repeat Revascularization n(%) 1 ( 3.4) 7 ( 0.6) 0.46 
  POAF n(%) 15 (51.7) 264 (21.4) <0.001 
  Renal replacement therapy n(%) 4 (13.8) 68 ( 5.5) 0.14 
  AKI n(%) 16 (55.2) 209 (17.0) <0.001 
  Sternal wound complication n(%) 1 ( 3.4) 34 ( 2.8) 1 
  Re-exploration for bleeding n(%) 3 (10.3) 37 ( 3.0) 0.09 
  RBC transfusion n(%) 17 (58.6) 148 (12.0) <0.001 
 
5-year outcomes ǂ    
   Mortality n(%) 4(13.8) 106(8.8) 0.3 
   MACCE n(%) 8(27.9) 167(14.0) 0.02 
   CV death n(%) 3(10) 48(4.0) 0.08 
   MI n(%) 2(6.9) 35(2.9) 0.18 
   CVA n(%) 1(3.4) 40(3.3) 0.92 
   Repeat Revascularization 4(13.8) 86(7.1) 0.12 
OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary artery bypass; PSM: 
propensity score matching; MI: myocardial infarction; IABP: intra-aortic balloon pump; 
POAF: postoperative atrial fibrillation; AKI: acute kidney injury; RBC: red blood cell; 
MACCE: major cardiac and cerebrovascular event; CV: cardiovascular; MI: myocardial 
infarction; CVA: cerebrovascular accident 
* Chi test or t-test 
ǂ Cox regression model   
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Table 5. Outcomes among OPCAB and matched ONCAB patients stratified for surgeon trial 
OPCAB volume  
 Matched ONCAB  OPCAB 
surgeon trial OPCAB 
volume quartiles 
0 1-5 6-60 >60 0 1-5 6-60 >60 
N of surgeons 95 33 25 3 95 33 25 3 
N of patients 688 340 204 28 - 62 530 668 
Hospital death n(%)  8 (1.2) 4 (1.2) 1 (0.5) 2 (7.1) - 3 (4.8) 3 (0.6) 6 (0.9) 
Conversion rate n(%) - - - - - 8(12.9) 14(2.6%) 7 (1.0%) 
N grafts mean(sd) 3.14 
(0.77) 
3.12 
(0.78) 
3.31 
(0.72) 
3.43 
(0.57) 
- 2.60 
(0.88) 
3.20 
(0.85) 
3.26 
(0.87) 
5-y Mortality n(%) 65(9.6) 22(6.7) 10(4.9) 5(17.9) - 5(8.2) 40 (7.8) 65(9.9) 
5-y MACCE n(%) 94(14.0) 44(13.4) 24(11.9) 7(25.7) - 9(14.9) 52(10.2) 114(17.5) 
5-y CV death n(%) 23(3.4) 8(2.4) 4(2.0) 28(14.3) - 3(4.8) 15(2.9) 33(5.0) 
5-y MI n(%) 23(3.4) 19(5.6) 8(3.9) 1(3.6) - 3(4.8) 9(1.7) 25(3.8) 
5-y CVA n(%) 16(2.4) 8(2.4) 6(3.0) 2(7.1) - 2(3.3) 16(3.1) 23(3.5) 
5-y Revascularization 
n(%) 
52(7.7) 16(4.9) 14(6.9) 28(7.1) - 3(5.0) 23(4.5) 64(9.7) 
OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary artery bypass; PSM: 
propensity score matching; MACCE: major cardiac and cerebrovascular event; CV: 
cardiovascular; MI: myocardial infarction; CVA: cerebrovascular accident 
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Supplementary Table 1. OPCAB, ONCAB and total number of cases performed according 
to individual surgeon  
 Surgeon# ONCAB OPCAB TOT 
Not available  74 60 134 
1 4 0 4 
2 0 1 1 
3 0 2 2 
4 0 2 2 
5 1 5 6 
6 1 0 1 
7 26 0 26 
8 18 0 18 
9 1 10 11 
10 0 1 1 
11 1 0 1 
12 16 0 16 
13 1 0 1 
14 1 1 2 
15 1 0 1 
16 4 0 4 
17 2 0 2 
18 4 0 4 
19 2 0 2 
20 37 0 37 
21 0 9 9 
22 8 2 10 
23 25 15 40 
24 28 1 29 
25 2 1 3 
26 1 0 1 
27 10 0 10 
28 1 0 1 
29 0 38 38 
30 21 0 21 
31 28 0 28 
32 20 0 20 
33 51 0 51 
34 9 0 9 
35 13 0 13 
36 0 15 15 
37 9 0 9 
38 17 0 17 
39 14 7 21 
40 10 0 10 
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41 63 17 80 
42 1 0 1 
43 5 0 5 
44 1 47 48 
45 18 1 19 
46 2 0 2 
47 3 0 3 
48 5 16 21 
49 2 0 2 
50 26 0 26 
51 0 6 6 
52 4 0 4 
53 1 0 1 
54 0 6 6 
55 20 1 21 
56 22 0 22 
57 4 43 47 
58 29 0 29 
59 37 0 37 
60 5 0 5 
61 0 10 10 
62 0 6 6 
63 53 4 57 
64 1 0 1 
65 15 0 15 
66 1 0 1 
67 5 0 5 
68 6 9 15 
69 3 0 3 
70 0 1 1 
71 6 0 6 
72 11 0 11 
73 1 0 1 
74 17 1 18 
75 25 0 25 
76 0 3 3 
77 32 0 32 
78 1 0 1 
79 2 47 49 
80 1 0 1 
81 26 0 26 
82 6 0 6 
83 1 1 2 
84 0 1 1 
85 0 48 48 
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86 1 77 78 
87 34 0 34 
88 37 0 37 
89 9 2 11 
90 1 0 1 
91 8 0 8 
92 3 0 3 
93 71 2 73 
94 7 2 9 
95 1 0 1 
96 13 0 13 
97 2 0 2 
98 1 34 35 
99 0 2 2 
100 1 0 1 
101 40 0 40 
102 1 0 1 
103 21 0 21 
104 27 8 35 
105 2 2 4 
106 31 2 33 
107 4 0 4 
108 6 12 18 
109 2 0 2 
110 11 20 31 
111 47 0 47 
112 0 3 3 
113 3 0 3 
114 1 0 1 
115 1 10 11 
116 1 0 1 
117 65 1 66 
118 1 0 1 
119 2 0 2 
120 18 5 23 
121 1 0 1 
122 26 5 31 
123 1 0 1 
124 1 8 9 
125 6 0 6 
126 1 0 1 
127 1 1 2 
128 6 0 6 
129 36 0 36 
130 5 1 6 
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131 2 18 20 
132 1 0 1 
133 7 0 7 
134 4 0 4 
135 1 0 1 
136 0 1 1 
137 0 412 412 
138 1 0 1 
139 1 0 1 
140 29 0 29 
141 0 2 2 
142 2 0 2 
143 5 11 16 
144 1 0 1 
145 1 0 1 
146 17 0 17 
147 9 1 10 
148 1 0 1 
149 19 0 19 
150 5 0 5 
151 1 0 1 
152 1 0 1 
153 76 1 77 
154 30 179 209 
155 6 0 6 
156 1 0 1 
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Supplementary Table 2. Baseline characteristics in patients undergoing OPCAB converted 
vs non-converted to on-pump 
 OPCAB not converted OPCAB converted 
to 
on-pump 
P* 
n  1231 29  
Age (years) mean (sd)  63.59 (9.06) 64.40 (9.77) 0.634 
Female n(%) 179 (14.5) 1 (3.4) 0.16 
BMI mean (sd)  28.10 (4.11) 28.15 (3.99) 0.95 
SBP (mmHg) mean (sd)  132.75 (19.11) 130.66 (17.94) 0.56 
DBP (mmHg) mean (sd)  75.40 (11.07) 72.48 (11.85) 0.16 
Creatinine (mmol/l) mean (sd)  99.68 (22.19) 107.76 (41.54) 0.06 
Treated Hypertension n(%) 919 (74.7) 24 ( 82.8) 0.44 
Treated Hyperlipaemia n(%) 1147 (93.2) 29 (100.0) 0.28 
Diabetes n(%)    0.78 
   No 959 (77.9) 21 (72.4)  
   Insulin dependent  68 ( 5.5) 2 (6.9)  
   Non-insulin dependent   204 (16.6) 6 (20.7)  
Smoking n(%)    0.02 
   Current 173 (14.1) 7 ( 24.1)  
   Ex-smoker  645 (52.4) 19 ( 65.5)  
   Never   413 (33.5) 3 ( 10.3)  
COPD n(%) 29 ( 2.4) 0 (  0.0) 0.83 
Asthma n(%) 58 ( 4.7) 5 ( 17.2) 0.009 
PVD n(%) 87 ( 7.1) 3 ( 10.3) 0.76 
TIA n(%) 40 ( 3.2) 0 (  0.0) 0.65 
CVA n(%) 40 ( 3.2) 0 (  0.0) 0.65 
MI n(%) 493 (40.0) 17 ( 58.6) 0.07 
PCI n(%) 199 (16.2) 9 ( 31.0) 0.06 
Preop AF n(%) 18 ( 1.5) 1 (  3.4) 0.92 
preop LVEF (%)    0.37 
     ≥50% (good)  927 (75.3) 23 ( 79.3)  
     31-49% (moderate)  264 (21.4) 4 ( 13.8)  
     ≤30% (poor)  40 ( 3.2) 2 (  6.9)  
LMD n(%) 276 (22.4) 6 ( 20.7) 1 
RA n(%) 231 (18.8) 9 ( 31.0) 0.15 
SVG n(%) 916 (74.4) 20 ( 69.0) 0.65 
BITA n(%) 582 (47.3) 16 ( 55.2) 0.51 
OPCAB: off-pump coronary artery bypass; SBP: systolic blood pressure; DPB: diastolic blood 
pressure; COPD: chronic obstructive pulmonary disease; PVD: peripheral vascular disease; 
TIA: transient ischemic attack; CVA: cerebrovascular accident; MI: myocardial infarction; 
PCI: percutaneous coronary intervention; AF: atrial fibrillation; LVEF: left ventricular ejection 
fraction; LMD: left main disease; RA: radial artery BITA: Bilateral internal thoracic arteries, 
SVG: saphenous vein graft 
*Chi test or t-test 
  
 30 
 
Supplementary Table 3. Baseline characteristics of OPCAB and matched ONCAB patients 
stratified for surgeon trial OPCAB volume  
 Matched ONCAB  OPCAB 
surgeon trial 
OPCAB volume 
quartiles 
0 1-5 6-60 
 
>60 
 
 0 
 
1-5 
 
6-60 
 
>60 
 
N of surgeons 95 33 25 3  95 33 25 3 
N of patients  688 340 204 28  - 62 530 668 
Age (years) mean 
(sd)  
64(9) 62(9) 6(9) 66(9)  - 64(8) 62(8) 65(9) 
Female n(%) 93 
(13.5) 
55 
(16.2) 
28 
(13.7) 
4 
(14.3) 
 - 7 
(11.3) 
55 
(10.4) 
118 
(17.7) 
BMI mean (sd)  28(4) 28(4) 28(4) 29(4)  - 27(4) 28 (4) 28(4) 
SBP (mmHg) mean 
(sd)  
133 
(17) 
132 
(17) 
133 
(21) 
134 
(15) 
 - 132 
(17) 
131 
(19) 
134 
(20) 
DBP (mmHg) mean 
(sd)  
75.50 
(11.51) 
74.91 
(10.99) 
75.22 
(11.02) 
72.72 
(13.01) 
 - 75.11 
(8.85) 
76.51 
(10.96) 
74.42 
(11.30) 
Creatinine (mmol/l) 
mean (sd)  
98 
(23) 
95 (20) 101 
(19) 
111 
(17) 
 - 94 
(31) 
96 (22) 104 
(22) 
Treated 
Hypertension n(%) 
508 
(73.8) 
272 
(80.0) 
146 
(71.6) 
24 
(85.7) 
 - 53 
(85.5) 
389 
(73.4) 
501 
(75.0) 
Treated 
Hyperlipaemia n(%) 
629 
(91.4) 
323 
(95.0) 
201 
(98.5) 
25 
(89.3) 
 - 59 
(95.2) 
516 
(97.4) 
601 
(90.0) 
Diabetes n(%)       -    
   No 540 
(78.5) 
257 
(75.6) 
163 
(79.9) 
23 
(82.1) 
 - 49 
(79.0) 
415 
(78.3) 
516 
(77.2) 
   Insulin dependent  28 
(4.1) 
24 
(7.1) 
13 
(6.4) 
2 
(7.1) 
 - 2 
(3.2) 
25 
(4.7) 
43 
(6.4) 
   Non-insulin 
dependent   
120 
(17.4) 
59 
(17.4) 
28 
(13.7) 
3 
(10.7) 
 - 11 
(17.7) 
90 
(17.0) 
109 
(16.3) 
Smoking n(%)       -    
   Current 78 
(11.3) 
50 
(14.7) 
18 
(8.8) 
3 
(10.7) 
 - 8 
(12.9) 
85 
(16.0) 
87 
(13.0) 
   Ex-smoker  384 
(55.8) 
196 
(57.6) 
131 
(64.2) 
12 
(42.9) 
 - 37 
(59.7) 
264 
(49.8) 
363 
(54.3) 
   Never   226 
(32.8) 
94 
(27.6) 
55 
(27.0) 
13 
(46.4) 
 - 17 
(27.4) 
181 
(34.2) 
218 
(32.6) 
COPD n(%) 14 
(2.0) 
6 (1.8) 8 (3.9) 0 (0.0)  - 1 
(1.6) 
11 
(2.1) 
17 
(2.5) 
Asthma n(%) 35 
(5.1) 
11 
(3.2) 
11 
(5.4) 
2 
(7.1) 
 - 2 
(3.2) 
24 
(4.5) 
37 
(5.5) 
PVD n(%) 45 
(6.5) 
20 
(5.9) 
14 
(6.9) 
2 
(7.1) 
 - 2 
(3.2) 
29 
(5.5) 
59 
(8.8) 
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TIA n(%) 18 
(2.6) 
10 
(2.9) 
11 
(5.4) 
1 
(3.6) 
 - 1 
(1.6) 
19 
(3.6) 
20 
(3.0) 
CVA n(%) 28 
(4.1) 
7 (2.1) 3 (1.5) 0 
(0.0) 
 - 1 
(1.6) 
11 
(2.1) 
28 
(4.2) 
MI n(%) 272 
(39.5) 
148 
(43.5) 
81 
(39.7) 
12 
(42.9) 
 - 28 
(45.2) 
226 
(42.6) 
256 
(38.3) 
PCI n(%) 102 
(14.8) 
63 
(18.5) 
46 
(22.5) 
3 
(10.7) 
 - 17 
(27.4) 
135 
(25.5) 
56 
(8.4) 
Preop AF n(%) 8  
(1.2) 
3 
(0.9) 
5 
(2.5) 
0 
(0.0) 
 - 0 
(0.0) 
7 
(1.3) 
12 
(1.8) 
preop LVEF (%)       -    
   ≥50% (good)  516 
(75.0) 
253 
(74.4) 
153 
(75.0) 
17 
(60.7) 
 - 52 
(83.9) 
405 
(76.4) 
493 
(73.8) 
   31-49% (moderate)  162 
(23.5) 
85 
(25.0) 
48 
(23.5) 
8 
(28.6) 
 - 10 
(16.1) 
112 
(21.1) 
146 
(21.9) 
   ≤30% (poor)  10 
(1.5) 
2 (0.6) 3 (1.5) 3 
(10.7) 
 - 0 
(0.0) 
13 
(2.5) 
29 
(4.3) 
LMD n(%) 149 
(21.7) 
85 
(25.0) 
34 
(16.7) 
9 
(32.1) 
 - 6 
(9.7) 
101 
(19.1) 
175 
(26.2) 
RA n(%) 137 
(19.9) 
84 
(24.7) 
27 
(13.2) 
4 
(14.3) 
 - 9 
(14.5) 
90 
(17.0) 
141 
(21.1) 
SVG n(%) 524 
(76.2) 
232 
(68.2) 
175 
(85.8) 
25 
(89.3) 
 - 38 
(61.3) 
400 
(75.5) 
498 
(74.6) 
BITA n(%) 308 
(44.8) 
171 
(50.3) 
85 
(41.7) 
11 
(39.3) 
 - 23 
(37.1) 
252 
(47.5) 
323 
(48.4) 
OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary artery bypass; SBP: 
systolic blood pressure; DPB: diastolic blood pressure; COPD: chronic obstructive pulmonary 
disease; PVD: peripheral vascular disease; TIA: transient ischemic attack; CVA: 
cerebrovascular accident; MI: myocardial infarction; PCI: percutaneous coronary intervention; 
AF: atrial fibrillation; LVEF: left ventricular ejection fraction; LMD: left main disease; RA: 
radial artery BITA: Bilateral internal thoracic arteries, SVG: saphenous vein graft  
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Figure Legend 
Central picture: 5-year cumulative incidence for mortality in the matched OPCAB and 
ONCAB groups. (OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary 
artery bypass) 
Figure 1. Study flow chart for patient inclusion/exclusion (OPCAB: off-pump coronary artery 
bypass; ONCAB: on-pump coronary artery bypass) 
Figure 2. 5-year cumulative incidence for mortality and major adverse cardiac and 
cerebrovascular events (MACCE) in the matched OPCAB and ONCAB groups. (OPCAB: 
off-pump coronary artery bypass; ONCAB: on-pump coronary artery bypass) 
Figure 3. 5-year cardiovascular(CV)-death, myocardial infarction (MI), cerebrovascular 
accident (CVA) and revascularization cumulative incidence in the OPCAB and ONCAB 
groups. (OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary artery 
bypass) 
Supplementary Figure 1. Propensity score density before and after matching  
Supplementary Figure 2. Changes in standardized mean difference for baseline 
characteristics between OPCAB and ONCAB before (red) and after matching (blue). (OPCAB: 
off-pump coronary artery bypass; SBP: systolic blood pressure; DPB: diastolic blood pressure; 
COPD: chronic obstructive pulmonary disease; PVD: peripheral vascular disease; TIA: 
transient ischemic attack; CVA: cerebrovascular accident; MI: myocardial infarction; PCI: 
percutaneous coronary intervention; AF: atrial fibrillation; LVEF: left ventricular ejection 
fraction; LMD: left main disease; RA: radial artery BITA: Bilateral internal thoracic arteries, 
SVG: saphenous vein graft) 
Supplementary Figure 3. 5-year cumulative incidence for mortality and major adverse cardiac 
and cerebrovascular events (MACCE) in the OPCAB group according to the incidence of 
conversion to on-pump. (OPCAB: off-pump coronary artery bypass) 
Supplementary Figure 4. 5-year cumulative incidence for mortality and major adverse cardiac 
and cerebrovascular events (MACCE) in the OPCAB and ONCAB groups according to 
surgeon trial OPCAB volume (0=performing on-pump only; 1-5 low OPCAB volume; 6-60: 
moderate volume; >60 high volume) (OPCAB: off-pump coronary artery bypass; ONCAB: on-
pump coronary artery bypass) 
Video 1. Off-pump coronary artery bypass grafting at Bristol Heart Institute 
